NCT07100405View on ClinicalTrials.gov

TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2028

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

PD-1 inhibitor

An approved agent (e.g., Pembrolizumab, Nivolumab, Sintilimab, Tislelizumab, etc.) will be selected based on clinical practice and administered at standard doses and schedules.

PROCEDURE

TACE

TACE is performed by using embolic agent combined with Lipiodol-pirarubicin emulsion per Investigator decision

Trial Locations (1)

200032

RECRUITING

Zhongshan Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER